A cute spontaneous intracerebral hemorrhage (ICH) is the least treatable and most serious form of stroke.
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Methods
The INTERACT2 study was an international, multicenter, openblinded end point, randomized controlled trial, the details of which are outlined elsewhere. 8 In brief, 2839 patients with computed tomographic-confirmed spontaneous ICH within 6 hours of onset and elevated systolic blood pressure (systolic BP, 150-220 mm Hg) were randomly assigned to receive intensive (target systolic BP, <140 mm Hg within 1 hour) or guideline-recommended (target systolic BP, <180 mm Hg) BP-lowering therapy using locally available agents according to standardized protocols. The study protocol was approved by the appropriate ethics committee at each participating site, and written informed consent was obtained from the patient or an appropriate surrogate.
Demographic and clinical characteristics were recorded at the time of enrollment. Stroke severity was measured using the Glasgow Coma Scale and National Institutes of Health Stroke Scale at baseline, 24 hours, and at day 7 (or earlier on discharge from hospital). Uncompressed digital images of all baseline and follow-up CT scans were collected in DICOM format, identified only with the patient's unique study number, for central analysis of ICH and IVH volumes blind to clinical data, treatment, and date and sequence of scan, using computer-assisted multislice planimetric and voxel threshold techniques in MIStar version 3.2 (Apollo Medical Imaging Technology). Inter-reader reliability was checked by periodic reanalysis of 15% of the scans reviewed by each imaging scientist against a gold standard single neurologist to avoid drift (intraclass correlation coefficient, 0.92 for total hematoma volume and 0.96 after removing outlier data with total volumes >50 mL).
The primary clinical outcome was death or major disability, defined by scores 3 to 6 on the modified Rankin Scale 9 at 90 days. Secondary outcomes were death and major disability (modified Rankin Scale score of 6 and 3-5, respectively), as well as serious adverse events and length of initial hospital stay.
Independent associations between various defined baseline characteristics and the presence of IVH at baseline were examined in a multivariable logistic regression model with all significant baseline characteristics as well as sex. Multivariable logistic regression models were also used to evaluate associations of baseline IVH volume, either as a continuous or categorical (thirds and fourths) variable, and clinical outcomes. These models included (1) initial adjustment for significant baseline univariates (including ICH volume, time to initial CT, randomized treatment, age, sex, China region, baseline systolic BP, location of ICH location [deep hemisphere versus other], history of heart disease, history of ischemic or undifferentiated stroke, and prior use of antithrombotic treatment [anticoagulation or antiplatelet agents]) and then with (2) further adjustment for significant differences in management variables >7 days postrandomization, 8 including the use of intubation (and ventilation), admission to an intensive care unit, prophylactic treatment for venous thromboembolism, use of any hemostatic therapy, any specific neurosurgical intervention, and a decision to withdraw active treatment/care. The predicted probabilities for outcomes were evaluated in univariate logistic regression models using IVH volume as a continuous variable. Collinearity and interaction between variables were checked. Data are presented with odds ratios (ORs) and 95% confidence intervals (CIs). Adjusted survival curves were used to assess survival in patients with and without IVH. A 2-sided P value <0.05 was set for statistical significance. All analyses were performed using SAS version 9.3 (SAS institute, Cary, NC).
Results
There were 2613 patients with ICH from the INTERACT2 trial with available CT data, of whom 740 (28%) had associated IVH at entry. Table 1 shows the characteristics of patients with and without IVH. In multivariable analysis, those with IVH were significantly older, more clinically severe (ie, higher National Institutes of Health Stroke Scale scores), having a slightly longer delay to initial (diagnostic) CT, higher heart rate, greater frequency of prior ischemic stroke, and larger volume of hematoma more often deeply located in the cerebral hemisphere.
As there was a strong correlation between China region and prophylactic treatment for venous thromboembolism (r=−0.74) among patients, the latter variable was excluded in further multivariable analysis. Four significant variable interactions were found which were also adjusted in the multivariable analysis: baseline hematoma volume and location, baseline hematoma volume and intubation, baseline hematoma volume and any neurosurgical intervention, and intubation and any neurosurgical intervention. , for the outcomes of death or major disability, death, and major disability alone, respectively. Other serious adverse outcomes were more frequent in patients with IVH, including any serious adverse event, clinical reported neurological deterioration, and specific noncardiovascular serious adverse events. Despite the differential prognosis between patients with and without IVH, there was no difference in their length of initial hospital stay. There were, however, significant differences in aspects of their medical and surgical management in the 7-day postrandomization, as outlined in Table 3 . In particular, patients with IVH received more intravenous BP-lowering treatment in the first 24 hours, any hemostatic therapy and ventricular drain insertion. Survival curves adjusted for imbalances in baseline characteristics show that the greatest probability of death from IVH occurred in the first 30 days after ICH onset and most apparent within the first several days ( Figure I in the online-only Data Supplement). After adjustment for differences in management, the survival curves were no longer significant ( Figure II in the online-only Data Supplement).
There was a strong and near continuous relationship between IVH volume and death (OR, 1.04; 95% CI, 1.02-1.06; P<0.01) as well as death or major disability (OR, 1.03; 95% CI, 1.01-1.05; P<0.01) at 90 days, in adjusted models according to increasing IVH volume (Figures 1 and 2 ). In Table 4 and the Table in the online-only Data Supplement, with baseline IVH volume divided into thirds and fourths categories, respectively, the threshold for significantly increased OR seemed lower for mortality (≈5 mL) than for the combined poor outcome of death or major disability (≈10 mL) with adjustment for baseline variables. The strength of these associations diminished after further adjustment for differences in management. There was no such trend in OR across similar categories of IVH volume and major disability alone.
Discussion
Our post hoc analysis of the INTERACT2 data set confirms that IVH denotes a worse outcome in patients with acute ICH. As well as showing a strong and near continuous relationship between IVH volume and the odds of death, and of death or major disability, logistic regression analysis identified volume of between 5 and 10 mL as being a statistically significant threshold for increased odds of poor clinical outcomes, whether defined by death or death and major disability, after adjustment for baseline imbalances. This volume of IVH seems meaningful for clinical decision making on prognosis and as a therapeutic target for residual IVH in those patients who have a ventricular drain inserted. When the model includes adjustment for ventricular drain and other management imbalances, more modest associations of IVH and these outcomes were evident.
Although the literature is consistent for IVH being a predictor of poor outcome in ICH, [10] [11] [12] [13] [14] [15] there is uncertainty on the strength and pattern of association. One study suggests a curvilinear relationship between IVH volume and 30-day mortality, with 10 to 15 mL of IVH proposed as an appropriate threshold for predicting poor outcome in patients with comatose state (Glasgow Coma Scale scores <8), 5 whereas another study indicates IVH volumes >20 mL as being relevant for survival. 13 Our analyses indicate a near linear relationship between the amount of IVH and adverse outcomes in ICH, with a much lower volume threshold than previously considered for increased odds of death (≈5 mL) and the combined poor outcome of death or major disability (or dependency, ≈10 mL).
The pathophysiological mechanisms underlying the independent prognostic significance of IVH are relatively well understood. Obstructive hydrocephalus and meningeal irritation from blood and its breakdown products obstruct arachnoid granulations, which are key to draining cerebrospinal fluid into dural venous sinuses, although intracranial pressure may not necessarily be increased. 16 Ependymal inflammation and fibrosis also contribute to delayed clearance of cerebrospinal fluid, which may further contribute to tissue damage caused from the primary parenchymal ICH. 10, 17 The weaker association of IVH with major disability is likely explained by residual disability in survivors being more strongly related to neuronal injury resulting from the underlying intraparenchymal hematoma. Furthermore, the weaker association of IVH and the primary outcome and mortality after adjustment for differences in management between randomized groups suggests potential beneficial effects of some interventions, in particular, the insertion of a ventricular drain.
Major strengths of this study are that it was undertaken on a large heterogeneous sample of patients recruited from a diverse range of hospitals and healthcare settings, who were assessed according to a standardized protocol and objective measures. This approach allowed adjustment for multiple confounding variables and provides some reassurance over both the reliability and the validity of the results. 
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Even so, we recognize several limitations, in particular that some patients such as those with large hematomas and who required early neurosurgery were excluded, leading to the influence of selection bias on a clinical trial population. However, this is likely to have led to an underestimation rather than overestimation of the prognostic significance of IVH. Another issue is that although our results are based on prospectively collected data, this is a retrospective study and thus prone to random error and incomplete adjustment for potential confounding including decisions on the *Adjusted for age, sex, China region, time to computed tomographic scan, baseline blood pressure, history of heart disease, history of ischemic stroke or undifferentiated stroke, prior use of warfarin/aspirin, baseline hematoma volume and location, randomized treatment, and interaction between baseline hematoma volume and location.
†Number of events. ‡Counts correspond to the number of subjects who experienced a specific serious adverse event at least once; 1 subject may be counted in >1 category.
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http://stroke.ahajournals.org/ Downloaded from management of patients. Finally, as two thirds of participants were from China, differences in the patterns of ICH and background care from other regions may raise concerns over the robustness of these results. In summary, this study reaffirms the importance of IVH as a major independent prognostic factor in patients with acute spontaneous ICH, in particular for predicting early mortality. Our approach defined not only a strong near linear association between IVH volume and poor outcome but also a statistically significant, and potentially clinically important, categorical threshold of 5 to 10 mL. This threshold may be useful for informing clinical-decision pathways and to indicate the need to consider early neurosurgical intervention, for example, external ventricular drainage. The results of ongoing studies such as the Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage (CLEAR III) trial 18 are eagerly awaited to provide a basis for further validation of these results and advance the treatment of IVH. Predicted probabilities for death by baseline intraventricular volume. *Adjusted factors are age, sex, China region, time to computed tomographic scan, baseline blood pressure, history of heart disease, history of ischemic stroke or undifferentiated stroke, prior use of warfarin/aspirin, baseline hematoma volume and location, randomized treatment. †Additional adjustment for all baseline characteristics in model 1 together with the use of intubation, intensive care unit admission, any hemostatic therapy, any surgical intervention, decision to withdraw active treatment and care, and interactions of baseline hematoma volume and location, baseline hematoma volume and intubation, baseline hematoma volume and any neurosurgical intervention, and intubation and any neurosurgical intervention. AOR indicates adjusted odds ratio; CI, confidence interval; IVH, intraventricular hemorrhage; and OR, odds ratio. Data are n (%) unless otherwise stated. AOR indicates adjusted odds ratio; CI, confidence intervals; IVH, intraventricular hemorrhage; and OR, odds ratio. *Adjusted factors are age, sex, China region, time to computed tomographic scan, baseline blood pressure, history of heart disease, history of ischemic stroke or undifferentiated stroke, prior use of warfarin/aspirin, baseline hematoma volume and location, randomized treatment, and interaction between baseline hematoma volume and location.
†Additional adjustment for all baseline characteristics in model 1 together with and significant management variables including the use of intubation, admission to an intensive care unit, use of any hemostatic therapy, any neurosurgical intervention, a decision to withdraw active treatment and care and interactions of baseline hematoma volume and location, baseline hematoma volume and intubation, baseline hematoma volume and any neurosurgical intervention, and intubation and any neurosurgical intervention. IVH denotes intraventricular hemorrhage; ICH, intracerebral hemorrhage; OR, odds ratio; AOR, adjusted odds ratio; and CI, confidence intervals. *Adjusted factors are: age, sex, China region, time to CT scan, baseline blood pressure, history of heart disease, history of ischemic or undifferentiated stroke, prior use of warfarin/aspirin, baseline hematoma volume and location, randomized treatment, and interaction between baseline hematoma volume and location. † Additional adjustment for all baseline characteristics in model 1 together with significant management variables including use of intubation, admission to an intensive care unit, use of any hemostatic therapy, any neurosurgical intervention, a decision to withdraw active treatment and care, and 4 interactions: baseline hematoma volume and location; baseline hematoma volume and intubation; baseline hematoma volume and any neurosurgical intervention; intubation and any neurosurgical intervention. 
